The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Largely fine and dry overnight with just a few showers at times. Temperatures will tumble away so frost is likely!
A team from the Brecon Beacons National Park is airlifting nearly a thousand tonnes of stone and heather for major landscape repairs.
Cardiff City owner Vincent Tan has given his full support to under-fire Manager Russell Slade